The tumor suppressor protein p53 is mutated in more than half of all human cancers. Several drugs that potentially can restore mutant p53 to its normal cancer-killing function are in clinical investigation.
Aug 31, 2021
0
108
Researchers at Karolinska Institutet in Sweden have published new findings in the journal Cancer Discovery showing how pharmacological activation of the protein p53 boosts the immune response against tumours. The results ...
Jul 6, 2021
0
7
A new study by an international team of researchers, led by NYU Abu Dhabi Associate Professor of Biology Mazin Magzoub, provides important insights into the p53 protein, a critical tumor suppressor often mutated and deactivated ...
Jun 29, 2021
0
10
Scientists at VCU Massey Cancer Center have identified a protein that operates in tandem with a specific genetic mutation to spur lung cancer growth and could serve as a therapeutic target to treat the disease.
Apr 19, 2021
0
137
Exposure to radiation can wreak indiscriminate havoc on cells, tissues, and organs. Curiously, however, some tissues are more vulnerable to radiation damage than others.
Feb 9, 2021
0
72
Researchers at the University of Gothenburg now suggest a possible cure for children with hard-to-treat forms of neuroblastoma using a new combination of drugs. In a new study in the journal Cancer Research, they describe ...
Jan 7, 2021
0
12
A new study from the UPF and WEHI (the Walter and Eliza Hall Institute of Medical Research) in Melbourne, Australia, has described the role of p53 target gene Zmat3 in lymphoma and lung cancer development. The study, conducted ...
Nov 30, 2020
0
5
The latest animation technology has revealed the molecular detail of how our bodies are protected from cancer by a key 'tumour suppressor' protein called p53.
Nov 11, 2020
0
15
Rare inherited mutations in the body's master regulator of the DNA repair system—the TP53 gene—can leave people at a higher risk of developing multiple types of cancer over the course of their lives. Now, for the first ...
Jul 16, 2020
0
10
The development of pancreatic cancer is driven by co-existing mutations in an oncogene involved in controlling cell growth, called KRAS, and in a tumor suppressor gene, called p53. But how these mutations cooperate to promote ...
Jun 18, 2020
0
94
